Although the goal was 100-fold selectivity for JAK3 over JAK2, the compound ultimately inhibited JAK1 and JAK2 as well, which turned out to be beneficial for broader anti-inflammatory effects, particularly in diseases like rheumatoid arthritis and IBD (Figure 1) [48,49]. Here, JAK2 is linked to inflammatory bowel disease.